Status:

COMPLETED

Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?

Lead Sponsor:

University of California, Los Angeles

Conditions:

Opioid-Induced Hyperalgesia

Eligibility:

All Genders

21-55 years

Phase:

PHASE2

Brief Summary

Utilizing a double-blind, placebo-controlled design, the proposed work will evaluate the ability of an adjuvant anticonvulsant analgesic to diminish or reverse the opioid-induced hyperalgesia complica...

Eligibility Criteria

Inclusion

  • Potential participants must:
  • Be between the ages of 21 and 55 years of age.
  • DSM-IVR diagnosis of prescription opioid abuse or dependence disorder
  • Be compliant in methadone treatment
  • On a stable dose of methadone at least 6 weeks.
  • Have provided random urine samples absent of any non-prescribed drugs of abuse x 2 months
  • Be in good physical health or in the case of a medical condition needing ongoing treatment, be in the care of a physician who is willing to take responsibility for such treatment. The same conditions apply in cases of patients with a psychiatric disorder needing ongoing treatment.
  • Be agreeable to and capable of signing an informed consent.

Exclusion

  • Potential participants must not:
  • Have known sensitivity to gabapentin.
  • Be substance dependent on alcohol, benzodiazepine, methamphetamine, cocaine or other drugs of abuse (except nicotine).
  • Have any acute medical condition that would make participation medically hazardous, (e.g., acute hepatitis, unstable cardiovascular disease, liver or renal disease) or have liver enzyme values (AST or ALT) greater than 5 times normal range.
  • Be acutely psychotic, severely depressed and in need of inpatient treatment, or an immediate suicide risk.
  • Have a neurological or psychiatric illness (i.e., schizophrenia, Raynaud's disease, urticaria, stroke) that would affect pain responses.
  • Be currently taking opioid analgesic medication for a painful condition on a regular basis.
  • Be a nursing or pregnant female. Female of childbearing potential must agree to use a medically acceptable method of birth control, (e.g. oral contraceptives, barrier (diaphragm or condom) with or without spermicide, levonorgestrel implant, intra-uterine progesterone contraceptives system, medroxyprogesterone acetate contraceptive injection) or to complete abstinence. Females who become pregnant during the course of the study will be dropped from the study.
  • Have a current or past history of high blood pressure, heart disease, stroke or currently have a pacemaker.

Key Trial Info

Start Date :

September 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2010

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT01210079

Start Date

September 1 2002

End Date

May 1 2010

Last Update

April 6 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UCLA School of Nursing

Los Angeles, California, United States, 90095